Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ongoing, recruiting
Participants planned
48
Countries
1
Sites
1
chronic liver disease
Key facts
- Sponsor
- Bionorica SE
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Trial duration
- 14 Jan 2026 → ongoing
- Decision date (initial)
- 2025-11-17
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2025-522423-95-00
- WHO UTN
- U1111-1325-0199
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
chronic liver disease
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Bionorica SE
- Sponsor organisation
- Bionorica SE
- Address
- Kerschensteinerstrasse 11-15
- City
- Neumarkt I.D.Opf.
- Postcode
- 92318
- Country
- Germany
Scientific contact point
- Organisation
- Bionorica SE
- Contact name
- Bernd Röther
Public contact point
- Organisation
- Bionorica SE
- Contact name
- Bernd Röther
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Germany | Ongoing, recruiting | 48 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Germany | 2026-01-14 | 2026-01-19 |
Application history
3 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-10-10 | Germany | Acceptable 2025-11-12
|
2025-11-17 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2025-12-05 | Germany | Acceptable | 2025-12-12 |
| 3 | SUBSTANTIAL MODIFICATION | SM-2 | 2026-03-05 | Germany | Acceptable 2026-03-18
|
2026-03-19 |